GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » EBIT per Share

Cleo Diagnostics (ASX:COV) EBIT per Share : A$ (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics EBIT per Share?

Cleo Diagnostics's EBIT per Share for the six months ended in Dec. 2023 was A$-0.02. Cleo Diagnostics does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cleo Diagnostics's EBIT per Share or its related term are showing as below:

ASX:COV's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 5.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Cleo Diagnostics's EBIT for the six months ended in Dec. 2023 was A$-2.59 Mil.


Cleo Diagnostics EBIT per Share Historical Data

The historical data trend for Cleo Diagnostics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics EBIT per Share Chart

Cleo Diagnostics Annual Data
Trend Jun23
EBIT per Share
-0.06

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23
EBIT per Share - -0.03 -0.02

Cleo Diagnostics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cleo Diagnostics's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

EBIT per Share(A: Jun. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.619/26.260
=-0.06

Cleo Diagnostics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

EBIT per Share(Q: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.585/128.500
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleo Diagnostics  (ASX:COV) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Cleo Diagnostics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics (ASX:COV) Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines